Uncommon Cures® was launched in 2023 with the mission to streamline orphan drug clinical development, which is unnecessarily slow, expensive, and likely to fail due to non-drug factors. Led by an expert team of physicians, nurses, and pharmacists with over 150 years of combined experience, Uncommon Cures collaborates with pharmaceutical and biotechnology sponsors to design and conduct highly efficient clinical trials for FDA and other regulatory agency approval. Some have called Uncommon Cures® a Clinical Research Organization (CRO) - it is not. Rather, it is a Clinical Research Program providing thought partnership and an efficient end-to-end solution called Uncommon Sense™ covering activities throughout orphan drug clinical development, including all legacy CRO and study site functions. By optimizing the clinical development process and prioritizing patient well-being, Uncommon Cures® aims to bring life-changing therapies to patients faster and more efficiently.

Biotechnology

Clinical Trials

Health Care

Uncommon Cures®

Uncommon Cures®'s headquarters in Chevy Chase, United States

Marshall Summar

Rob Freishtat

Penny Toren

Christiana Bakare

Tom Moreno

Shan Lu

Tamanna Roshan Lal Mb Chb

Description

People (4)

Penny Toren

Marshall Summar

Mimi Fenton

Tom Moreno

Jobs